Home >> Industry News >> All The News
frontview no frame frontview vmo3D sideview no frame sideview vmo3D
  • Also available via:

Jan Marini acknowledges validity of Allergan's patent for eyelash enhancement PDF
Submit Your News
Tuesday, 22 July 2008
Allergan, Inc. announced that it has agreed to dismiss its legal action against Jan Marini Skin Research, Inc. ("Jan Marini"), one of the defendants in Allergan's patent infringement lawsuit pending in the United States District Court for the Central District of California. The dismissal is based on Jan Marini acknowledging the validity of Allergan's relevant patents covering the use of certain drug substances, such as prostaglandin analogs, to promote eyelash enhancement and also agreeing to cease its distribution of eyelash products containing these ingredients in the United States and other countries worldwide where Allergan owns related patents.

As recently announced, Allergan has completed a clinical program with its patented formulation of bimatoprost, a synthetic prostaglandin analog, and will pursue United States Food and Drug Administration approval to market a product to stimulate eyelash growth in the United States.

"We are pleased that Jan Marini has acknowledged that Allergan's U.S. and foreign eyelash growth patents are valid and enforceable and has agreed to cease further distribution of its eyelash growth products," said Douglas S. Ingram, Allergan's Executive Vice President, Chief Administrative Officer, General Counsel and Secretary. "Allergan has a significant intellectual property estate covering this area. Allergan has sued, or is evaluating suit against, a number of infringers for refusing to respect our intellectual property rights. As evidenced by our ongoing lawsuit against those companies and individuals who have chosen to market unapproved eyelash products containing active pharmaceutical ingredients, Allergan will not idly stand by while others infringe our intellectual property rights."

Source: Allergan
Five new acquisitions for Essilor PDF
Submit Your News
Monday, 21 July 2008
In its recent half year financial report Essilor reports five new acquisitions in Europe, the United States and Asia.

In Germany, a majority interest has been acquired in Nika GmbH, a lens wholesaler that is the country’s exclusive distributor of Nikon products. Based in Winningen (Rhineland-Palatinate), the company has revenues of roughly €9 million. Its purchase is designed to strengthen the close fit between Essilor’s German distributor networks.

In the United States, the prescription laboratory network has been further strengthened by Essilor of America’s acquisition of majority stakes in Deschutes (based in Oregon and Idaho, with revenues of $2.7 million) and Optimatrix (based in Alabama, with revenues of $4.6 million).

In Malaysia, Essilor has acquired the country’s leading independent laboratory Frame N’ Lenses. With revenues of €2 million and a local market share of 5%, the new subsidiary will improve the Company’s control over the local distribution of its entry-level products. In India, Essilor has acquired the assets of Sankar & Co’s ophthalmic division, comprising five formerly franchised laboratories in the Coimbatore region, which together generate €0.9 million in revenues. In particular, the new unit will develop a Crizal® anti-reflective lens center.

Source: Essilor
Carl Zeiss Vision ophthalmic lenses updated PDF
Submit Your News
Product News
Monday, 21 July 2008
The Carl Zeiss Vision ophthalmic lenses product data have been updated on with the assistance of Carl Zeiss Vision Australia.
Apologies ordered after patient left blind PDF
Submit Your News
New Zealand News
Monday, 21 July 2008
In New Zealand, a former Southland Hospital ophthalmologist and the Southland District Health Board have been directed to apologise to an Invercargill man (picture) who was left legally blind after a lack of follow-up care.

In a recent report, Health and Disability Commissioner Ron Paterson says former Southland Hospital eye surgeon Dr B, whom The Southland Times has identified as Brett Rogers, and the board both breached guidelines in the treatment of the patient.

Dr Rogers and the board breached the Code of Health and Disability Services Consumers' Rights of Graham Moodie by failing to provide him with the appropriate standard of care, the report says.

Southland District Health Board interim chief executive Brian Rousseau said the board accepted the findings.

Essilor Ophthalmic Lenses product data updated PDF
Submit Your News
Product News
Friday, 18 July 2008
Essilor Ophthalmic Lenses product data have been updated at with the support from Essilor Australia.
<< Start < Prev 221 222 223 224 225 226 227 228 229 230 Next > End >>

Page 224 of 283